Locally Advanced Urothelial Carcinoma
Oncology·MeSH: Carcinoma, Transitional Cell
Prevalence
61.0 / 100K
Incidence
18.0 / 100K/yr
6 drugs in development·1 company·8 clinical trials
Drug Pipeline by Phase
Phase 2(5)
Phase 1(1)
| Drug | Company |
|---|---|
| TYRA-300 | Tyra Biosciences, Inc. (TYRA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Locally Advanced Urothelial Carcinoma?
BioSniper tracks 6 drugs in development for Locally Advanced Urothelial Carcinoma across 1 company.
How many clinical trials target Locally Advanced Urothelial Carcinoma?
There are 8 clinical trials targeting Locally Advanced Urothelial Carcinoma tracked by BioSniper.
What is the prevalence of Locally Advanced Urothelial Carcinoma?
The estimated prevalence of Locally Advanced Urothelial Carcinoma is approximately 61.0 per 100,000 population.
Deep-dive into Locally Advanced Urothelial Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis